A long‐acting GDF15 analog causes robust, sustained weight loss and reduction of food intake in an obese nonhuman primate model
Open Access
- 23 May 2023
- journal article
- research article
- Published by Wiley in Clinical and Translational Science
- Vol. 16 (8) , 1431-1444
Abstract
Growth Differentiation Factor‐15 (GDF15) is a circulating polypeptide linked to cellular stress and metabolic adaptation. GDF15's half‐life is ~3 h and activates the glial cell line‐derived neurotrophic factor family receptor alpha‐like (GFRAL) receptor expressed in the area postrema. To characterize sustained GFRAL agonism on food intake (FI) and body weight (BW), we tested a half‐life extended analog of GDF15 (Compound H [CpdH]) suitable for reduced dosing frequency in obese cynomolgus monkeys. Animals were chronically treated once weekly (q.w.) with CpdH or long‐acting GLP‐1 analog dulaglutide. Mechanism‐based longitudinal exposure‐response modeling characterized effects of CpdH and dulaglutide on FI and BW. The novel model accounts for both acute, exposure‐dependent effects reducing FI and compensatory changes in energy expenditure (EE) and FI occurring over time with weight loss. CpdH had linear, dose‐proportional pharmacokinetics (terminal half‐life ~8 days) and treatment caused exposure‐dependent reductions in FI and BW. The 1.6 mg/kg CpdH reduced mean FI by 57.5% at 1 week and sustained FI reductions of 31.5% from weeks 9–12, resulting in peak reduction in BW of 16 ± 5%. Dulaglutide had more modest effects on FI and peak BW loss was 3.8 ± 4.0%. Longitudinal modeling of both the FI and BW profiles suggested reductions in BW observed with both CpdH and dulaglutide were fully explained by exposure‐dependent reductions in FI without increase in EE. Upon verification of the pharmacokinetic/pharmacodynamic relationship established in monkeys and humans for dulaglutide, we predicted that CpdH could reach double digit BW loss in humans. In summary, a long‐acting GDF15 analog led to sustained reductions in FI in overweight monkeys and holds potential for effective clinical obesity pharmacotherapy.Keywords
All Related Versions
This publication has 34 references indexed in Scilit:
- Effects of the once-daily GLP-1 analog liraglutide on gastric emptying, glycemic parameters, appetite and energy metabolism in obese, non-diabetic adultsInternational Journal of Obesity, 2013
- The once‐daily human GLP‐1 analogue liraglutide impacts appetite and energy intake in patients with type 2 diabetes after short‐term treatmentDiabetes, Obesity and Metabolism, 2013
- TGF-b Superfamily Cytokine MIC-1/GDF15 Is a Physiological Appetite and Body Weight RegulatorPLOS ONE, 2013
- Anorexia/cachexia of chronic diseases: a role for the TGF‐β family cytokine MIC‐1/GDF15Journal of Cachexia, Sarcopenia and Muscle, 2012
- Macrophage Inhibitory Cytokine 1 (MIC-1/GDF15) Decreases Food Intake, Body Weight and Improves Glucose Tolerance in Mice on Normal & Obesogenic DietsPLOS ONE, 2012
- Quantification of the effect of energy imbalance on bodyweightThe Lancet, 2011
- IRINI: Random group allocation of multiple prognostic factorsContemporary Clinical Trials, 2011
- Quantitative Prediction of Human Pharmacokinetics for Monoclonal AntibodiesClinical Pharmacokinetics, 2011
- Tumor-induced anorexia and weight loss are mediated by the TGF-β superfamily cytokine MIC-1Nature Medicine, 2007
- Identification, expression and functional characterization of the GRAL geneJournal of Neurochemistry, 2005